Overview

Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva

Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to: (1) examine the secrection of risperidone (RIS) (Risperdal) and its metabolite, 9-OH-RIS, in saliva, (2) determine the concentration ratio of RIS and 9-OH-RIS between plasma and saliva, and (3) compare the rate of decline in concentration of RIS and 9-OH-RIS in saliva and plasma by measurements at timed intervals during a single dosing interval.
Details
Lead Sponsor:
Ohio State University
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Paliperidone Palmitate
Risperidone